Annals of Surgical Oncology

, Volume 20, Issue 9, pp 2958–2963 | Cite as

Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETs): An Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone)

  • Giovenzio Genestreti
  • Luca Ampollini
  • Marco Angelo Burgio
  • Luigi Rolli
  • Stefano Sanna
  • Emanuela Scarpi
  • Manuela Monti
  • Luca Burgio Salvatore
  • Luciana Giannone
  • Antonio Santo
  • Maurizio Mezzetti
  • Claudia Casanova
  • Roberta Buosi
  • Michele Rusca
  • Dino Amadori
  • Giampaolo Gavelli
Endocrine Tumors

Abstract

Background

This multicenter analysis evaluated patient outcome and clinical pathologic features of thymic epithelial tumors after complete surgical resection and adjuvant treatment.

Methods

Histologic classification and clinical staging were performed according to WHO classification and Masaoka staging system, respectively.

Results

We analyzed 62 patients, 20 (32 %) of whom had myasthenia at diagnosis. Clinical and pathologic staging was as follows: 31 (50 %) and 30 (48 %) patients had stage I disease, 19 (30 %) and 22 (35 %) stage II, 5 (8 %) and 3 (6 %) stage III, 2 (4 %) and 2 (3 %) stage IVa, and 5 (8 %) and 5 (8 %) stage IVb, respectively. Histologic examination revealed 11 (19%) type A tumors, 19 (30%) type AB tumors, 7 (12 %) type B1 tumors, 11 (17 %) type B2 tumors, 11 (17 %) type B3 tumors, and 3 (5 %) type C tumors. Adjuvant therapies comprised chemotherapy in 3 (5 %) patients and radiotherapy in 16 (26 %) patients. Median follow-up was 71 months (range 1–145). DFS and OS at 48, 60, and 72 months were 89 and 89 %, 86 and 97 %, and 95% and 92%, respectively. Myasthenia at the onset of disease (P = 0.18 for DFS; P = 0.97) and tumor size >5 cm (P = 0.94 for DFS; P = 0.56) were not prognostic factors.

Conclusions

TETs are rare and indolent tumors. Complete surgical resection followed by adjuvant therapies, such as chemotherapy and/or radiotherapy, in patients at risk of recurrence show very good DFS and OS results, even in cases with radically resected pleural-pulmonary metastases.

Keywords

Overall Survival Thymoma Thymic Carcinoma Thymic Epithelial Tumor Masaoka Stage 

Notes

Acknowledgment

The authors thank GIPO (Gruppo Interdisciplinare di Pneumo-Oncologia) for coordinating the collection of clinical data. They also thank Ursula Elbling for editing this manuscript.

Disclosure

The authors have no conflicts of interest or financial ties to disclose.

References

  1. 1.
    Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol. 1978;9:495–515.PubMedCrossRefGoogle Scholar
  2. 2.
    Lattes R. Thymomas and other tumors of the thymus: an analysis of 107 cases. Cancer. 1962;15:1224–60.CrossRefGoogle Scholar
  3. 3.
    Lewis JE, Wick MR, Scheithauer BW, Bernatz PE, Talyor WF. Thymoma: a clinicopathologic review. Cancer. 1987;60:2727–43.PubMedCrossRefGoogle Scholar
  4. 4.
    Loehrer PJ Sr, Wick MR. Thymic malignancies. Cancer Treat Res. 2001;105:277–302.PubMedCrossRefGoogle Scholar
  5. 5.
    LeGolvan DP, Abell MR. Thymomas. Cancer. 1977;39:2142–57.PubMedCrossRefGoogle Scholar
  6. 6.
    Masaoka A, Hashimoto T, Shibata K, Yamakowa Y, Nakamae K. Thymomas associated with pure red cell aplasia: histology and following studies. Cancer. 1989;64:1872.PubMedCrossRefGoogle Scholar
  7. 7.
    Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48:2485–92.PubMedCrossRefGoogle Scholar
  8. 8.
    Batata MA, Martini N, Huvos AG, Aguilar RI, Beattie EJ Jr. Thymomas: clinico-pathologic features, therapy and prognosis. Cancer. 1974;34:389–96.PubMedCrossRefGoogle Scholar
  9. 9.
    Monden Y, Nakahara K, Iioka S, et al. Recurrence of thymoma: clinico-pathological features, therapy, and prognosis. Ann Thorac Surg. 1985;39:165–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymoma: results of 241 operated cases. Ann Thorac Surg. 1991;51:152–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Bernatz PE, Khonsari S, Harrison EG Jr, Taylor WF. Thymoma: factors influencing prognosis. Surg Clin North Am. 1973;53:885–92.PubMedGoogle Scholar
  12. 12.
    Quintanilla-Martinez L, Wilkins EW Jr, Choi N, Efird J, Hug E, Harris NL. Thymoma. Histologic subclassification is an independent prognostic factor. Cancer. 1994;74:606–17.PubMedCrossRefGoogle Scholar
  13. 13.
    Sugiura H, Morikawa T, Ito K, Ono K, Okushiba S, Satoshi K, Katoh H. Long-term results of surgical treatment for invasive thymoma. Anticancer Res. 1999;19(2B):1433–7.Google Scholar
  14. 14.
    Curran WJ, Kornstein MJ, Brooks JJ, Turrisi AT III. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol. 1988;6:1722–7.PubMedGoogle Scholar
  15. 15.
    Haniuda M, Miyazawa M, Yoshida K, et al. Is postoperative radiotherapy for thymoma effective? Ann Surg. 1996;224:219–24.PubMedCrossRefGoogle Scholar
  16. 16.
    Uematsu M, Yoshida H, Kondo M, et al. Entire hemithorax irradiation following complete resection in patients with Stage II–III invasive thymoma. Int J Radiat Oncol Biol Phys. 1996;35:357–60.PubMedCrossRefGoogle Scholar
  17. 17.
    Latz D, Schraube P, Oppitz U, et al. Invasive thymoma: treatment with postoperative radiation therapy. Radiology. 1997;204:859–64.PubMedGoogle Scholar
  18. 18.
    Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1.320 patients from Japan. Ann Thorac Surg. 2003;76:878–85.PubMedCrossRefGoogle Scholar
  19. 19.
    Rosai J. Histological typing of tumours of the thymus. In: WHO International histological classification of tumours, 2nd ed. New York: Springer-Verlag; 1999:5–15.Google Scholar
  20. 20.
    Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer. 1991;68(1):30–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Loehrer PJ Sr, Perez CA, Roth LM, Greco A, Livingston RB, Einhorn LH. Chemotherapy for advanced thymoma. Preliminary results of an intergroup study. Ann Intern Med. 1990;113:520–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRefGoogle Scholar
  23. 23.
    Cox DR. Regression models and life tables. J Royal Stat Soc. 1972;34:187–220.Google Scholar
  24. 24.
    Okereke IC, Kesler KA, Morad MH, et al. Prognostic indicators after surgery for thymoma. Ann Thorac Surg. 2010;89:1071–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Monden Y, Nakahara K, Nanjo S, Fujii Y, Matsumura A, Masaoka A, Kawashima Y. Invasive thymoma with myasthenia gravis. Cancer. 1984;54:2513–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymectomy in myasthenia gravis. Results of 662 cases operated upon in 15 years. Eur J Cardio-Thorac Surg. 1989;3:504–11.Google Scholar
  27. 27.
    Wright CD, Wain JC, Wong DR, Donahue DM, Gaissert HA, Grillo HC, Mathisen DJ. Predictors of recurrence in thymic tumors: importance of invasion, and size. World Health Organization histology. J Thorac Cardiovasc Surg. 2005;130:1413–21.PubMedCrossRefGoogle Scholar
  28. 28.
    Rieker RJ, Hoegel J, Morresi-Hauf A, Hofmann WJ, Blaeker H, Penzel R, Otto HF. Histologic classification of thymic epithelial tumors: comparison of established classification schemes. Int J Cancer. 2002;98:900–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Gupta R, Marchevsky AM, McKenna RJ, Wick M, Moran C, Zakowski MF, Suster S. Evidence based pathology and the pathologic evaluation of thymomas: transcapsular invasion is not a significant prognostic feature. Arch Pathol Lab Med. 2008;132:926–30.PubMedGoogle Scholar
  30. 30.
    Okereke IC, Kesler KA, Morad MH. Prognostic indicators after surgery for thymoma. Ann Thorac Surg. 2010;89:1071–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Lucchi M, Melfi F, Dini P, et al. Neoadjuvant chemotherapy for stage III and IV-A thymoma; a single institution experience with long term follow-up. J Thorac Oncol . 2006;1:308–13.PubMedCrossRefGoogle Scholar
  32. 32.
    Okereke IC, Kesler KA, Freeman RK, et al. Thymic carcinoma: outcomes after surgical resection. Ann Thorac Surg. 2012;93:1668–72.PubMedCrossRefGoogle Scholar
  33. 33.
    Bott MJ, Wang H, Travis W, et al. Management and outcomes of relapse after treatment for thymoma and thymic carcinoma. Ann Thorac Surg. 2011;92:1984–92.PubMedCrossRefGoogle Scholar
  34. 34.
    Welsh JS, Wilkins KB, Green R, Bulkley G, Askin F, Diener-West M, Howard SP. Association between thymoma and second neoplasms. JAMA. 2000;283:1142–3.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Giovenzio Genestreti
    • 1
  • Luca Ampollini
    • 2
  • Marco Angelo Burgio
    • 3
  • Luigi Rolli
    • 2
  • Stefano Sanna
    • 4
  • Emanuela Scarpi
    • 5
  • Manuela Monti
    • 5
  • Luca Burgio Salvatore
    • 3
  • Luciana Giannone
    • 6
  • Antonio Santo
    • 6
  • Maurizio Mezzetti
    • 7
  • Claudia Casanova
    • 8
  • Roberta Buosi
    • 9
  • Michele Rusca
    • 2
  • Dino Amadori
    • 3
  • Giampaolo Gavelli
    • 10
  1. 1.Department of Clinical OncologyCervesi HospitalCattolicaItaly
  2. 2.Department of Thoracic SurgeryUniversity HospitalParmaItaly
  3. 3.Department of Medical OncologyIRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST-IRCCS)MeldolaItaly
  4. 4.Department of Thoracic SurgeryMorgagni-Pierantoni HospitalForlìItaly
  5. 5.Unit of Biostatistics and Clinical TrialsIRST-IRCCSMeldolaItaly
  6. 6.Department of Medical OncologyUniversity HospitalVeronaItaly
  7. 7.Department of Thoracic SurgeryS. Carlo Borromeo HospitalMilanItaly
  8. 8.Department of Medical OncologySanta Maria delle Croci HospitalRavennaItaly
  9. 9.Department of Clinical OncologyMaggiore della Carità HospitalNovaraItaly
  10. 10.Radiology UnitIRST-IRCCSMeldolaItaly

Personalised recommendations